Month: July 2020

PALO ALTO, Calif., July 08, 2020 (GLOBE NEWSWIRE) — Tesla will post its financial results for the second quarter of 2020 after market close on Wednesday, July 22, 2020. At that time, Tesla will issue a brief advisory containing a link to the Q2 2020 update, which will be available on Tesla’s Investor Relations website. Tesla management will hold a live question and answer webcast that day at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) to discuss the Company’s financial and business results and outlook.What: Date of Tesla Q2 2020 Financial Results and Q&A WebcastWhen: Wednesday, July 22, 2020Time: 2:30 p.m. Pacific Time / 5:30 p.m. Eastern TimeQ2 2020 Update: http://ir.tesla.com  Webcast: http://ir.tesla.com (live and replay)Approximately two hours after the Q&A session, an archived version of the webcast will be available...

REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be approximately $156.0 million, excluding any exercise of the underwriters’ option...

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) — Argonaut Gold Inc.(TSX: AR) (the “Company”, “Argonaut Gold” or “Argonaut”) confirms the filing of the Technical Report (see press release dated July 3, 2020) in relation to its Florida Canyon mine in Nevada, USA, pursuant to National Instrument 43-101 of the Canadian Securities Administrators.

VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (TSX.V: STND) (“Standard Uranium” or the “Company”) announces that its board of directors has authorized the payment of a one-time performance incentive bonus (the “Incentive Bonus”) to the President and Chief Executive Officer of the Company, Jon Bey. The Incentive Bonus is intended to compensate Mr. Bey for services provided in connection with the successful listing of the Company on the TSX Venture Exchange (the “Exchange”), and to reflect the below market compensation Mr. Bey agreed to accept during the initial listing and financing process.“The Board of Directors commends Mr. Bey for his substantial efforts over the past two years. His successful guidance of the Company through the Exchange listing process and initial financing rounds has added...

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) — Skyline Investments Inc. (the “Company” or “Skyline”) (TASE: SKLN) respectfully announces the following:Further to the description in the Company’s Board of Directors Report for 2019 (Reference No. 2020-01-027372) and further to the description in the supplementary immediate report dated April 14, 2020 (Reference No. 2020-01-038355) an amendment to the conditional agreement dated March 10, 2020 (the “Amendment”) for the sale of the Company’s Port McNicoll site (the “Site”), was signed on July 8, 2020 (the “Transaction”). As stipulated in the Amendment, the Buyer will waive its due diligence condition and the sale price of the Site will be CAD $33.5 million of which CAD $1 million will be used to cover legal and sale brokerage fees. In accordance with the Amendment, the Buyer paid the Company...

DRAPER, Utah, July 08, 2020 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), today announced the pricing of the previously announced underwritten public offering of shares of its common stock. HealthEquity has agreed to sell an aggregate of 4,600,000 shares of its common stock at a price to the public of $56.00 per share.  Gross proceeds to HealthEquity from the offering are expected to be $257,600,000. The offering is expected to close on July 13, 2020, subject to customary closing conditions. Additionally, HealthEquity has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares of its common stock.  HealthEquity intends to use the net proceeds from the offering to free up additional capital for organic and inorganic growth by pre-paying $200 million under its...

First large study in constitutional genetic diseases showed 100% concordance to gold-standard cytogenetic testingIn patients with leukemia, Saphyr enabled crucial discoveries including novel fusion events never described before in that diseaseSaphyr solved previously unidentified genetic diseases by finding novel mutationsMaking continued progress on goal to become the new standard of digital cytogenetic testingSAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two top cytogeneticists from leading institutions in The Netherlands and France presented their research data as part of a multicentric, international effort to compare data generated with Bionano’s Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients...

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its second quarter 2020 earnings in a press release to be issued after the market closes on Tuesday, July 28, 2020.Senior management will hold a conference call for its second quarter 2020 earnings on Wednesday, July 29, 2020 at 8:00 a.m. Pacific Time (“PT”).  Conference call access information is as follows:Toll Free Number: 1 (877) 868-5513Pass Code: 4494304A telephonic replay of the conference call will be available beginning at 2:00 p.m. PT on Wednesday, July 29, 2020 through Wednesday, August 5, 2020.  Replay access information is as follows:Toll Free Number: 1 (855) 859-2056Pass Code: 4494304About American Assets Trust, Inc.                                                  American Assets Trust, Inc. is a full service,...

Daix (France), July 8, 2020 – Inventiva (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, today announced the formal commencement of bookbuilding and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue and sell, subject to market and other conditions, a total of 7,478,261 ordinary shares of the Company in an initial public offering of American Depositary Shares (“ADSs”), each representing one ordinary share, in the United States (the “U.S. Offering”) and a concurrent offering...

Daix (France), le 8 Juillet 2020 – Inventiva (Euronext Paris: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique (« NASH »), des mucopolysaccharidoses (« MPS ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le début formel de la procédure de construction du livre d’ordres et le dépôt d’un « amendment » (avenant) au document d’enregistrement (Form F-1) pour y inclure une fourchette de prix indicative dans le cadre de son projet d’offre, sous réserve notamment des conditions de marché, d’un total de 7 478 261 actions ordinaires de la Société. Ce projet d’offre comprend une offre d’American Depositary...